Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the third quarter in 2010. This includes net product sales of $10.6 million recognized from the sale of DIFICID™. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.

  • For the quarter ended September 30, 2011, the $10.6 million in net sales to wholesalers reflected a total of 4,335 DIFICID treatments
  • 2,505 DIFICID treatments were shipped from wholesalers to hospitals, retail pharmacies and long-term care facilities in the quarter ended September 30, 2011
  • 535 hospitals had ordered DIFICID as of September 30, 2011
  • 304 hospitals had placed DIFICID on formulary, and 346 hospital formulary reviews were pending as of October 21, 2011.

  • "In only a few months since our first DIFICID sale on July 19th we've seen significant interest in DIFICID converting into uptake and adoption. We reported $10.6 million in sales to our wholesalers in the third quarter, and we expect continued strong uptake as the launch progresses," said Pedro Lichtinger, President and CEO of Optimer. "This confirms our belief that DIFICID meets the need for a Clostridium difficile-associated diarrhea treatment addressing the problem of recurrence by providing a sustained clinical response. As the medical community becomes more familiar with and recognizes the value of DIFICID, we anticipate that adoption will continue."Optimer reported a net loss for the third quarter of 2011 of $26.4 million, or ($0.57) 
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
    10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
    11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the addition ... to their offering. , Global Market Report ... Trypsin globally and regionally ( Europe , ... Latin America etc.). It captures Trypsin ... report focuses on three primary areas; manufacture methods & technology ...
    (Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
    (Date:2/27/2015)... , Feb. 27, 2015   PureTech , a ... and commercializing disruptive products and technologies in the healthcare ... , former CEO and Member of the Board of ... "It,s has been a pleasure to know ... that we will be working together more closely now," ...
    (Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
    Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
    ... 28, 2011 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... the WBBA Life Science Innovation Northwest Conference on Thursday, ... 607 of the Washington State Conference Center, Seattle, Washington. ... 3, 201110:25 AM PST/1:25 PM EST/7:25 PM CETRoom 607, ...
    ... a professor of chemistry at Penn State University, has developed ... zinc selenide -- a light-yellow compound that can be used ... allows for a more effective and liberal manipulation of light, ... Such technology could be applied to the development of improved ...
    ... 25, 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... and tests innovative HIV/AIDS vaccines, today announced its financial results ... GeoVax reported a net loss of $478,784 for ... a net loss of $843,275 for the comparable period in ...
    Cached Biology Technology:New kind of optical fiber developed 2New kind of optical fiber developed 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 4GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 5GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 6
    (Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
    (Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
    (Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
    Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
    ... , Leipzig. Fallow agricultural land and steppe-formation processes ... on global air quality than was previously assumed. This ... dust cloud that formed over parched fields in southern ... matter in Central Europe. On 24 March 2007 the ...
    ... a protein in the blood linked to defence ... previously understood in the bodys immune defence system. ... of how the body defends against disease and heals ... protein, Properdin discovered only half a century ago- can ...
    ... Ind. -- The asteroid presumed to have wiped out ... carbon deep in the Earth,s crust liquefied, rocketed skyward, ... say scientists from the U.S., U.K., Italy, and New ... known to geologists as carbon cenospheres, cannot be formed ...
    Cached Biology News:Arable land can have a negative impact on air quality 2Arable land can have a negative impact on air quality 3Arable land can have a negative impact on air quality 4Arable land can have a negative impact on air quality 5New discovery on role of vital protein that fights meningitis 265-million-year-old asteroid impact triggered a global hail of carbon beads 265-million-year-old asteroid impact triggered a global hail of carbon beads 3
    ... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
    Request Info...
    ... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
    LTBP-1 (E-20)...
    Biology Products: